Roche Czech Republic made a net profit of CZK 252 mil with revenues of CZK 4,962 mil in 2016, up by 394% and down by 8.88%, respectively, compared to the previous year. This translates into a net margin of 5.08%.
Historically, between 2003 - 2016, the firm’s net profit reached a high of CZK 252 mil in 2016 and a low of CZK 3.04 mil in 2003. Since 2011, the firm's net profit has increased 399% or 37.9% a year on average.
On the operating level, EBITDA reached CZK 475 mil, up 127% compared to the previous year. Over the last five years, company's EBITDA has risen 18% a year on average.
As far as Roche Czech Republic's peers are concerned, Pfizer Czech Republic posted net and EBITDA margin of 2.26% and 3.69%, respectively in 2016, Bayer Czech Republic generated margins of 4.04% and 5.38% and Amgen Czech Republic profit margin reached 5.03% on the net and 6.20% on the EBITDA level in 2019.
You can see all the company’s data at Roche Czech Republic profile, or you can download a report on the company in the report section.
Helgi Library 
